Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Retained Earnings: 2023-2024

Historic Retained Earnings for Compass Therapeutics (CMPX) over the last 2 years, with Dec 2024 value amounting to -$364.7 million.

  • Compass Therapeutics' Retained Earnings fell 18.82% to -$415.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$415.5 million, marking a year-over-year decrease of 18.82%. This contributed to the annual value of -$364.7 million for FY2024, which is 15.66% down from last year.
  • Latest data reveals that Compass Therapeutics reported Retained Earnings of -$364.7 million as of FY2024, which was down 15.66% from -$315.3 million recorded in FY2023.
  • Compass Therapeutics' Retained Earnings' 5-year high stood at -$315.3 million during FY2023, with a 5-year trough of -$364.7 million in FY2024.
  • For the 2-year period, Compass Therapeutics' Retained Earnings averaged around -$340.0 million, with its median value being -$340.0 million (2023).
  • Data for Compass Therapeutics' Retained Earnings shows a maximum YoY declined of 15.66% (in 2024) over the last 5 years.
  • Compass Therapeutics' Retained Earnings (Yearly) stood at -$315.3 million in 2023, then dropped by 15.66% to -$364.7 million in 2024.